Anaphore cultures $25M for protein treatments
Biotech firm Anaphore has raised $25 million in first-round funding to continue development of protein therapies for cancer and immune diseases. The money, which includes $8 million in seed financing received in March, is enough to push a couple of its drugs into clinical trials.
In particular, Anaphore works to create artimers — treatments manufactured from naturally secreted human serum protein. The La Jolla, Calif.-based company says they are more efficient to produce and easier to… Continue Reading
MDV hires pros to find personalized medicine investments
Mohr Davidow Ventures, a Menlo Park, Calif. firm, has hired two biotech experts to help it make prudent investments in personalized healthcare companies. Essentially, they will look for startups that apply technology to give patients more control over their medical experiences, and to cut costs for care providers and drug developers.
Daniel Riskin — who actually worked as a surgeon before entering industry — and Phyllis Whiteley both have firsthand experience at biotechnology companies. Riskin, named… Continue Reading